# 1 Genomic and clinical characteristics of campylobacteriosis in Australia

- 2 Danielle M Cribb<sup>1\*</sup>, Cameron RM Moffatt<sup>2</sup>, Rhiannon L Wallace<sup>3</sup>, Angus T McLure<sup>1</sup>, Dieter Bulach<sup>4,5</sup>,
- 3 Amy V Jennison<sup>2</sup>, Nigel French<sup>6</sup>, Mary Valcanis<sup>5</sup>, Kathryn Glass<sup>1</sup>, Martyn D Kirk<sup>1</sup>.
- 4 1. National Centre for Epidemiology and Population Health, the Australian National University,
- 5 Canberra, Australia
- 6 2. Queensland Health Forensic and Scientific Services, Coopers Plains, Brisbane, Australia
- 7 3. Agriculture and Agri-Food Canada, Agassiz Research and Development Centre, Agassiz,
- 8 British Columbia, Canada
- 9 4. Melbourne Bioinformatics, The University of Melbourne, Melbourne, Australia
- 10 5. Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for
- 11 Infection and Immunity, The University of Melbourne, Melbourne, Australia
- 12 6. Tāwharau Ora|School of Veterinary Science, Massey University, Palmerston North, New
- 13 Zealand
- 14
- 15 \* corresponding author
- 16 <u>Danielle.Cribb@anu.edu.au</u> (DC)

17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 18 Abstract

*Campylobacter* spp. are a common cause of bacterial gastroenteritis in Australia, primarily acquired
 from contaminated meat. We investigated the relationship between genomic virulence characteristics
 and the severity of campylobacteriosis, hospitalisation, and other host factors.

We recruited 571 campylobacteriosis cases from three Australian states and territories (2018–2019). We collected demographic, health status, risk factors, and self-reported disease data. We whole genome sequenced 422 *C. jejuni* and 84 *C. coli* case isolates along with 616 retail meat isolates. We classified case illness severity using a modified Vesikari scoring system, performed phylogenomic analysis, and explored risk factors for hospitalisation and illness severity.

27 On average, cases experienced a 7.5-day diarrhoeal illness with additional symptoms including 28 stomach cramps (87.1%), fever (75.6%), and nausea (72.0%). Cases aged ≥75 years had milder symptoms, lower Vesikari scores, and higher odds of hospitalisation compared to younger cases. 29 30 Chronic gastrointestinal illnesses also increased odds of hospitalisation. We observed significant 31 diversity among isolates, with 65 C. jejuni and 21 C. coli sequence types. Antimicrobial resistance genes were detected in 20.4% of isolates, but multidrug resistance was rare (0.04%). Key virulence genes 32 33 such as cdtABC (C. jejuni) and cadF were prevalent (>90% presence) but did not correlate with disease 34 severity or hospitalisation. However, certain genes appeared to distinguish human *C. jejuni* cases from 35 food source isolates.

Campylobacteriosis generally presents similarly across cases, though some are more severe. Genotypic virulence factors identified in the literature to-date do not predict disease severity but may differentiate human *C. jejuni* cases from food source isolates. Host factors like age and comorbidities have a greater influence on health outcomes than virulence factors.

Keywords: antimicrobial resistance, Campylobacter, clinical outcomes, severity, virulence, whole
genome sequencing.

# 42 Author summary

This study focused on *Campylobacter*, a common cause of gastroenteritis in Australia. We explored
the relationship between *Campylobacter's* genomic characteristics and disease severity,
hospitalisation, and host-related factors.

In 2018 – 2019, we collected data from 571 campylobacteriosis cases from Eastern Australia, focusing
on demographics, health status, risk factors, and self-reported symptoms. We sequenced 422 *C. jejuni*and 84 *C. coli* case isolates and 616 retail meat isolates. We used a modified Vesikari scoring system
to assess illness severity, performed phylogenomic analysis, and explored hospitalisation and severity
risk factors.

51 Cases experienced an average 7.5-day period of diarrhoea with additional symptoms including 52 stomach cramps, fever, and nausea. Older individuals (75+ years) had milder symptoms but a higher 53 chance of hospitalisation. Those with chromic gastrointestinal conditions faced increased 54 hospitalisation odds. Case isolates showed considerable diversity. Antimicrobial resistance genes were 55 detected in some isolates, but multidrug resistance was rare. Virulence genes did not predict severity or hospitalisation, but some genes did differentiate between case and food source C. jejuni isolates. 56 Host-related factors including age and comorbidities are more important in determining health 57 58 outcomes.

# 60 Introduction

61 *Campylobacter* spp. are the most commonly reported cause of bacterial gastroenteritis globally [1], 62 with Australia having among the highest rates in industrialised countries [2-4]. Most Campylobacter 63 infections are acquired from consumption of contaminated meat, primarily poultry [1, 5, 6]. The 64 clinical features of campylobacteriosis range from mild acute illness with diarrhoea, abdominal 65 cramps, and fever to severe enterocolitis with prolonged abdominal pain and bloody diarrhoea [7, 8]. 66 While disease is mostly self-limiting, some cases require antimicrobial therapy and hospitalisation [7, 67 9]. Some symptoms and host factors (e.g., age and chronic illness) are more likely to predict healthcare use for acute gastrointestinal illness [10, 11]. Previous studies have found vomiting, bloody diarrhoea, 68 69 infective dose, fever, and loss of appetite associated with longer illness duration and risk of 70 hospitalisation [12, 13].

Pathogen virulence and host susceptibility factors explored in microbiological studies may have implications for disease presentation and outcomes for *Campylobacter* spp. However, specific virulence mechanisms associated with severe illness have not been clearly defined due to the genetic diversity and uniqueness of the pathogen [14-16]. The main mechanisms associated with pathogenesis in enteric bacteria are motility, adhesion, colonisation, toxin production, invasion, and immune modulation [8, 16-20].

Identifying specific genes or gene combinations responsible for particular virulence phenotypes enables understanding of the mechanisms of *Campylobacter* infection. While microbiological studies have identified genes associated with putative virulence factors, there is a lack of epidemiological studies confirming the role these genes play in disease manifestation. In this study we characterise notified Australian campylobacteriosis cases by severity and compare with the genomic characteristics of *Campylobacter* spp. isolated from food and humans.

# 83 Methods

#### 84 Case selection and recruitment

We recruited 571 notified campylobacteriosis cases from the Australian Capital Territory (ACT), Hunter 85 86 New England health district of New South Wales (NSW), and Queensland (Qld) between February 2018 87 and October 2019, as part of a previously described large Australian study [6, 21]. Suspected 88 campylobacteriosis cases provided stool samples to local pathology laboratories to identify and isolate 89 the pathogen. Samples that were positive for *Campylobacter* spp. were reported to the state or 90 territory public health department. Isolates were referred to reference laboratories and processed for whole genome sequencing (WGS). Cases, or their legal guardian if aged less than 18 years, provided 91 92 consent for study enrolment. Interviews were generally conducted within two weeks of laboratory 93 notification, by either ACT public health unit staff (ACT cases) or by a computer-assisted telephone interview team (NSW and Qld cases). Interviewers collected information on case characteristics 94 95 (demographics, medication use, health conditions), a list of self-reported symptoms, and disease 96 characteristics. Cases were asked to confirm their diarrhoeal status during illness (>3 loose bowel 97 movements in any 24-hour period), the date of illness onset, that no household member had 98 diarrhoea or tested positive for *Campylobacter* in the four weeks prior to illness onset, and that they had not travelled outside of Australia in the two weeks prior to illness onset [21]. 99

#### 100 Modified Vesikari Scoring System

We modified the Vesikari scoring system (VSS) [22] to characterise illness severity (Table 1): retained duration of diarrhoea in days and maximum number of diarrhoeal stools in a 24-hour period; replaced the 'treatment type' variable (i.e., rehydration or hospitalisation) with 'healthcare use' (primary care, 1-2 days in hospital, or  $\geq 3$  days in hospital), and; substituted the presence of symptoms for clinical characteristics as these data were not collected from our self-reported cases. We defined hospitalisation as being admitted overnight due to campylobacteriosis. These modifications are consistent with studies that categorised bacterial gastroenteritis in paediatric cases [23, 24]. We

- allocated equal weighting to variables associated with the course of disease as well as each reported
- symptom apart from blood in stool, which was given two points (Table 1) [25]. We classified cut-offs
- 110 for mild, moderate, and severe disease as ≤8 points, 9–12 points, and ≥13 points respectively, in line
- 111 with previous scoring systems [22-24].

112	Table 1. Modified Vesikar	i scoring system for ca	ampylobacteriosis in A	Australian children	and adults, 2018-2019.
<b>TT</b>		i scoring system for co	inpyrobucteriosis in r		unu uuuns, 2010 2015.

	Score			
	0	1	2	3
Symptom presentation				
Vomiting	No	Yes	-	-
Self-reported fever	No	Yes	-	-
Stomach cramps	No	Yes	-	-
Headache	No	Yes	-	-
Nausea	No	Yes	-	-
Muscle and body aches	No	Yes	-	-
Blood in stool	No	-	Yes	-
Course of disease				-
Duration of diarrhoeal	0	1–3	4–6	≥7
illness (days)				
Maximum number of	<3*	3–5	6–10	≥11
bowel movements in				
any 24-hour period				
Healthcare use	-	Primary care	1–2 days in	≥3 days in
		(notified case)	hospital	hospital
Score classification: ≤8 mild, 9–12 moderate, ≥13 severe				
*Exclusion criterion for ca	se definition			

## 113 Food sample collection

- 114 Raw chicken meat and offal (organ meat) and beef, lamb, and pork offal were collected from retail
- outlets in NSW, Qld, and Victoria (chicken only) from 2017–2019, and from the ACT in 2018, as
- 116 previously described [26, 27]. Offal samples included giblets, neck, liver, kidney, heart, and tongue. As
- 117 *Campylobacter* spp. prevalence is generally low on beef, lamb, and pork meat, offal was sampled to
- 118 obtain a suitable number of isolates for WGS.

#### 119 Whole genome sequencing and genomic analysis

- 120 For each *Campylobacter* isolate, genomic DNA was extracted and WGS was performed using an
- 121 Illumina NextSeq500 (Illumina, San Diego, California, USA) as described previously [27]. In total, we
- sequenced 508 isolates from human stool samples and 616 isolates from retail meat and offal. Kraken2

123 confirm classification was used to taxonomic and isolate purity (https://pubmed.ncbi.nlm.nih.gov/31779668/); two isolates from two human cases were confirmed 124 125 as C. lari and were excluded from this analysis. De novo assembly of the genome sequence for each 126 isolate from sequencing reads was performed using SPAdes (https://pubmed.ncbi.nlm.nih.gov/32559359/). The multi-locus sequence type (MLST) was 127 128 determined from each isolate using the MLST software (v2.19.0; https://github.com/tseemann/mlst) 129 and the PubMLST Campylobacter jejuni/coli database [28]. Isolate genome sequences were also 130 screened for resistance determinants using the abriTAMR pipeline (v1.0.7; https://github.com/MDU-AMRFinderPLUS 131 PHL/abritamr) and the database (v3.10.16; https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/). Virulence genes 132 133 present in each isolate genome sequence were detected using Abricate 134 (https://github.com/tseemann/abricate) with genes from the Virulence Factor Database (VFDB) [29]. 135 The parameters used for gene detection were the top hit with >80% gene coverage and >80% nucleic 136 acid sequence identity. Abricate was found to be unsuitable for detecting the porA and the flaA gene 137 in this set of isolates. The paralogous *flaA* and *flaB* genes caused assembly issues which resulted in 138 incomplete flaA assemblies. The gene peptide sequence ADKAMDEQLKILDTIKTKATQAAQDGQSLKTRTM from near the N-terminus of FlaA was found to be 139 140 encoded in a contig from each assembly. Subsequently, the presence of the complete *flaA* and *flaB* 141 genes was inferred by mapping reads from each isolate to the *flaA* gene of *C. jejuni* strain NCTC11168. 142 For porA, a protein level detection using the PorA protein from C. jejuni strain NCTC11168 as the 143 subject for a blast search against the assembled genome of each isolate was used due to sequence 144 identity less than 80%. Core genome comparison of isolates within a species was performed using Bohra (https://github.com/MDU-PHL/bohra). The genome sequences of C. jejuni strain RM1221 145 146 (NC\_003912) and C. coli strain 76339 (NC\_022132) were used as reference genome sequences for the C. jejuni and C. coli core genome comparisons respectively. 147

## 148 Inference of antimicrobial resistance phenotype

149 We used resistance genes and mutations to infer phenotypic resistance (Table S1) in agreement with 150 our previous phenotypic testing results [30]. We investigated chromosomal mutations in the bla<sub>OXA-61</sub> 151 promotor region, the 23S rRNA gene, and the quinolone resistance determining region of qyrA, as previously described [27]. Ampicillin (AMP) resistance was inferred from a point mutation at position 152 153 57 in the  $bla_{0XA-61}$  promotor region, associated with gene expression inactivation [31]. Resistance to 154 erythromycin (ERY) was determined based on the nucleotide at positions 2074 and 2075 of the 23S 155 rRNA gene [32]. Ciprofloxacin resistance (CIP) was determined by examining the amino acid at position 156 86 of GyrA (T86I confers resistance) [33]. The presence of the tet(O), aph(3')-Illa, and erm(B) genes 157 inferred resistance to tetracycline (TET), gentamicin (GEN), and ERY, respectively [34-36]. We defined 158 multi-drug resistance (MDR) as displaying a resistant gene profile for three or more antimicrobial drug classes [37]. Short-read WGS data for all isolates were deposited to the NCBI Sequence Read Archive 159 160 under bioprojects PRJNA592186, PRJNA560409, PRJNA591966 and 161 (https://www.ncbi.nlm.nih.gov/sra) (Table S2).

#### 162 Virulence factor analysis

163 We selected virulence genes that frequently occur in studies of genetic determinants of severe campylobacteriosis in humans [8, 38-40]. We compared the prevalence of each virulence gene in each 164 165 Campylobacter species in Australia with pooled prevalence from a small collection of isolates from 166 international studies. We also assessed virulence genotype clustering and total gene count by MLST. Additionally, we included the total number of virulence genes present in isolates as a categorical 167 168 predictor variable in generalised linear models described below. After excluding any genes that were 169 present or absent from all isolates, we used virulence genes to predict hospitalisation and long 170 diarrhoeal illness. Further, we compared virulence factors between food and case isolates to determine if these factors predict human campylobacteriosis. We tested multiple predictive modelling 171 172 methods including random forest, logic regression, and binary discriminant analysis [41-44]. We

173 considered Kappa statistic values >0.3 to indicate that the chosen model performed substantially
174 better than naïve classification.

#### 175 Statistical analysis

176 All data analyses were performed with R (version 4.0.2) [45]. We used Pearson's chi square test and 177 Student's t-test to assess statistical differences between categorical variable groups and means (p 178  $\leq$ 0.05). We fitted a generalised additive model with a logit link to predict prevalence of symptoms and 179 hospitalisation as a smooth function of age [46]. We used generalised linear models to calculate 180 adjusted odds ratios (aORs) for demographic factors, medication use, health conditions and disease profiles on the outcomes of hospitalisation, diarrhoeal disease lasting longer than seven days, and 181 182 antibiotic prescription following illness. We estimated aORs controlling for age group, gender, and 183 location, including any variables with a p-value  $\leq 0.2$  in a multivariable model. We used backward 184 stepwise logistic regression to identify variables for the final model (variables with p-values  $\leq 0.05$ ). 185 assessing significance, aORs and confidence intervals (CIs), and biological plausibility. We used gpplot2 186 to visualise all data figures, and used iToL (v5.0) for phylogenetic tree visualisation [47, 48].

187 Ethics

This study was approved by the Australian National University Human Research Ethics Committee (Ref. 2016/426), ACT Health Human Research Ethics Committee (Ref. ETH.8.17.168), Hunter New England Human Research Ethics Committee (Ref. 17/08/4.03), Qld Health Human Research Ethics Committee (Ref. RD007108), and the University of Melbourne Office of Research Ethics and Integrity (Ref. 1750366.1).

## 194 Results

#### 195 Symptom profiles and severity

196 We included 571 cases from the ACT (n = 93), NSW (n = 178) and Qld (n = 300). The highest proportion 197 of cases (38.8%, 219/565) reported experiencing 11–20 loose bowel movements within a 24-hour 198 period with a mean length of illness of 7.5 days (standard deviation [SD] 4.9), generally increasing with 199 age from 6.4 days (SD 3.0) in 5–14-year-olds to 8.7 days (SD 9.6) in ≥75-year-olds. Case patients 200 reported an average of four symptoms in addition to diarrhoea, frequently including stomach cramps 201 (87.1%; 487/559), fever (75.6%; 428/566) and nausea (72.0%; 393/546). Case age influenced symptom 202 profiles, with symptoms such as stomach cramps, fever, headaches, and blood in stool less commonly 203 reported in older cases (Fig1a and 1b). The proportion of cases hospitalised was 24.9% (142/571), 204 which increased with age from 10.2% (5/49) of 0–4-year-olds to 45.0% (18/40) of ≥75-year-olds 205 (Fig1c). Overall, 49.8% (283/568) of case patients reported that they were prescribed antibiotics 206 following illness, with 59.3% (83/140) of hospitalised cases reporting antibiotic prescription compared 207 to 46.7% (200/428) of non-hospitalised cases (p = 0.01). Cases as young as 15 years old reported using 208 proton-pump inhibitors (PPIs), a medication prescribed to treat stomach acid-related gastro-209 oesophageal disorders and to prevent ulcers [49, 50]. Thirty percent (39/130) of 35-54-year-olds 210 reported using PPIs, increasing to 37.5% (15/40) in  $\geq$ 75-year-olds. Symptom profiles were generally 211 similar between males and females. However, females were more likely to report stomach cramps 212 (91.1%, 216/237, p = 0.02) and nausea (80.7%, 188/233, p = 0.00) than males (84.2%, 271/322) and 65.5%, 205/313, respectively). There was no significant difference in the probability of hospitalisation 213 214 (25.5% [84/330] males, 24.1% [58/241] females) or duration of illness (7.4 days [SD 5.0] males, 7.6 215 days [SD 4.8] females). The mean VSS score was 10.7 (95% CI 5.7–15.7) (Fig 2). VSS scores were 216 influenced by age, with scores peaking in 15–34-year-olds (11.7, 95% Cl 7.6–15.8) and tapering off in 217 older adults ≥75 years (8.8, 95% CI 4.0–13.6) (Fig 3).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297105; this version posted October 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 219 Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches, nausea, and
- 220 stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis cases (blood in stool,
- 221 fever, headache, and vomiting), 2018–2019. (c) Course of disease characteristics of Australian
- 222 campylobacteriosis cases (hospitalisation, hospitalisation  $\geq$ 3 days, length of illness  $\geq$ 7 days), 2018–2019. The
- 223 solid lines indicate estimated prevalence from a univariable generalised additive model with a logit link.
- 224 Shading around each line represents the 95% confidence interval for the prevalence estimate.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297105; this version posted October 17, 2023. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.10.10.2029/109.110 version posted October 17, 2020. The copyright holder for this perperint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

229 Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in Australia, 230 2018–2019. Bars represent the percentage of cases reporting the corresponding Vesikari Score. Error bars are

231 calculated from binomial confidence intervals using the Pearson-Klopper exact method. Counts are provided 232 above the bar for each Vesikari Score.





234 Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis cases in 235 Australia, 2018–2019. The solid line indicates the estimated score from a generalised additive model with a

236 logit link. Shading around the line represents the 95% confidence interval for the score estimate.

237



We constructed three multivariable models, adjusting for age, sex, and location for the outcomes of hospitalisation, antibiotic prescription, and duration of illness for cases with a sequenced *Campylobacter* isolate (*n* = 506; Tables S3–S5). We found that vomiting (aOR 2.6, 95% Cl 1.5–4.6) and chronic gastrointestinal (GI) illness (e.g., Crohn's disease, irritable bowel syndrome, ulcerative colitis; aOR 4.4, 95% Cl 1.8–11.1) were associated with higher odds of hospitalisation (Table S3).

244 Factors associated with an increased odds of antibiotic prescription following illness included having 245 blood in stool (aOR 1.6, 95% CI 1.1–2.4), having diarrhoea lasting longer than seven days (aOR 2.0, 246 95% Cl 1.3 - 2.9), and being hospitalised (aOR 1.9, 95% Cl 1.1 - 3.2) (Table S4). Factors associated with increased odds of diarrhoeal disease lasting longer than seven days included having headaches (aOR 247 248 1.7, 95% CI 1.1–2.6) and taking proton pump inhibitors (PPIs) (aOR 2.0, 95% CI 1.2–3.3) (Table S5). We 249 found a cyclical relationship between hospitalisation, length of illness, and antibiotic prescription 250 following illness with these factors showing as significant in each model. We chose to report the most 251 biologically plausible pathways.

#### 252 Genetic diversity of clinical isolates

We included 422 *C. jejuni* and 84 *C. coli* isolates derived from human clinical samples in this study. *C. jejuni* isolates were assigned to 65 unique MLSTs while *C. coli* isolates were assigned to 21 (Table S6). The most common sequence types detected were ST50 for *C. jejuni* (17.8%, 75/422), and ST1181 for *C. coli* (27.4%, 23/84) (Table S6; S1 and S2 Figs). Pairwise core genome single nucleotide polymorphism (SNP) distances between *C. jejuni* isolates ranged from zero to ~37k SNPs, while *C. coli* isolates ranged from zero to ~82k SNPs.

#### 259 Antimicrobial resistance genes

We detected antimicrobial resistance (AMR) genes and point mutations in 20.4% (103/506) of the human isolates, with MDR genotype profiles in 0.04% (2/506) of isolates (Fig 4, S3 Fig, S4 Fig). Results for resistance determinants in the food isolates are reported elsewhere [27]. We did not detect AMP or CIP genomic resistance genes or mutations in one *C. jejuni* and 21 *C. coli* isolates, although this was

264 not tested phenotypically. The most common resistant mechanism detected was for CIP with 12.3% (62/505) of isolates (C. jejuni 13.1% [55/421], C. coli 8.3% [7/84]) and for TET at 9.7% (49/506) of 265 isolates (C. jejuni 11.1% [47/422], C. coli 2.4% [2/84]). An AMP resistant genotype was detected in 266 5.2% (25/485) of isolates (C. jejuni 5.7% [24/422], C. coli 1.6% [1/63]), with isolates possessing the 267  $bla_{OXA-184}$  gene (n = 3) or a  $bla_{OXA-61}$  gene and active promotor (n = 22; a point mutation at position 57 268 269 in the promotor regulates gene expression). A GEN resistant genotype was present in 0.4% (2/506) of 270 isolates (C. jejuni 0.2% [1/422], C. coli 1.2% [1/84]), and ERY resistant genotype was present in 0.2% 271 (1/506) of isolates (not detected in C. jejuni, 1.2% [1/84] in C. coli), possessing the 23S rRNA A2075G mutation. Two isolates were inferred to be MDR: one C. coli isolate harboured five antimicrobial 272 determinants (AMP, CIP, ERY, GEN, and TET) and one C. jejuni isolate harboured four (AMP, CIP, GEN, 273 274 and TET).

Fig 4. Genotypic antimicrobial resistance profiles of 506 *Campylobacter* isolates for ampicillin (AMP), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET). Isolates were classified as susceptible if they did not possess a known resistance gene or mutation (n = 403). The number of isolates possessing each resistance profile is noted above the respective bar. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact method.



## 281 Virulence factors

282 Human clinical C. jejuni isolates had a median of 96 virulence genes detected (range 82–118) and C. 283 coli isolates had a median of 72 genes (range 64–86). Two-thirds of screened genes were highly 284 conserved (≥95% present) across isolates in both species, with 68.1% (81/119) for C. jejuni, and 68.7% 285 (68/99) for C. coli. The flaA, flaB, and porA genes were present in all isolates through additional 286 screening. We detected virulence gene clustering by MLST (Table S6; S1 Fig; S2 Fig). Further, 14 of 19 287 and nine of 12 virulence genes selected for international comparison for C. jejuni, and C. coli, 288 respectively, were highly conserved across isolates, particularly those associated with adhesion and 289 colonisation (e.g., cadF, porA, and pebA), motility (e.g., flaA), cytotoxin production (e.g., cdtABC), and 290 invasiveness (e.g., ciaBC and flaC) (Table 2). Genes associated with immune modulation (e.g., cstIII and 291 neuABC) were present variably across C. jejuni isolates at approximately 35.0%. These genes were rare 292 or absent in C. coli isolates. Lipooligosaccharide (LOS) and capsule gene screening was limited to those 293 genes present in C. jejuni NCTC 11168.

294 We compared all virulence genes present in either our human isolates and 285 C. jejuni and 331 C. coli 295 isolates from meat and offal. Virulence gene pseE/maf5 was more common in C. jejuni food isolates than in case isolates while Cj1421c, Cj1422c, kpsC, rbfC, fliK, Cj1136, Cj1138, waaV, and wlaN were 296 297 more common in C. jejuni case isolates (Table S7). No isolates significantly differed between food and 298 human isolates for C. coli. We did not observe an association between the total number of virulence 299 genes present and the odds of longer duration of diarrhoeal illness, hospitalisation, or antibiotic 300 prescription following illness (Tables S3–S5). Random forest analyses of 58 C. jejuni and 43 C. coli 301 virulence genes with less than 100.0% prevalence across isolates did not detect any individual or 302 specific combinations of virulence genes that predicted severe illness or hospitalisation, nor did 303 analysis of 72 C. coli genes comparing campylobacteriosis case isolates with food isolates (Kappa < 0.3) 304 (S1 and S2 File). Analysis of 65 C. jejuni virulence genes comparing case and food isolates highlighted

- that some virulence genes such as *fliK, Cj1138,* and *Cj1136* were enriched in isolates from humans
- 306 (Kappa 0.51) (S5 Fig).

#### 307 Table 2. Comparison of prevalence of selected *Campylobacter* virulence genes in Australia and internationally.

	Gene	C. jejuni			C. coli		
Virulence function		Australian	International prevalence*		Australian	International prevalence*	
		prevalence ( <i>n</i> = 422) %	% (range)	<i>n/N</i> isolates (# studies)	prevalence ( <i>n</i> = 84) %	% (range)	<pre>n/N isolates (# studies)</pre>
	flaA†	100.0	100.0 (100.0 – 100.0)	185/185 (2)	100.0	-	-
	flhA	99.8	99.4 (99.4 – 99.4)	154/155 (1)	100.0	-	-
Motility, adhesion, and	cadF	100.0	99.6 (97.9 – 100)	600/602 (8)	100.0	85.1 (8.3 – 100.0)	63/74 (3)
colonisation	jlpA	99.8	98.4 (96.2 – 100.0)	185/188 (3)	_	100.0 (100.0 - 100.0)	9/9 (1)
	porA‡	100.0	90.4 (87.3 – 100.0)	123/136 (2)	100.0	59.5 (16.7 – 100.0)	25/42 (3)
	pebA	100.0	100.0 (100.0 – 100.0)	205/205 (3)	100.0	100.0 (100.0 - 100.0)	9/9 (1)
	ciaB	97.6	95.6 (50.0 – 100.0)	483/505 (7)	96.4	100.0 (100.0 - 100.0)	21/21 (2)
Invasion	ciaC	100.0	_	_	100.0	_	_
	flaC	100.0	96.8 (88.5 – 100.0)	251/257 (4)	100.0	100.0 (100.0 - 100.0)	42/42 (3)
	cdtA	99.3	96.7 (82.6 – 100.0)	442/457 (5)	_	36.5 (13.2 – 100.0)	27/74 (3)
Cutatovia and vation	cdtB	99.5	99.3 (97.1 – 100.0)	601/605 (8)	_	56.5 (49.1 – 100.0)	35/62 (2)
Cytotoxin production	cdtC	100.0	99.0 (94.1 – 100.0)	384/388 (4)	_	35.1 (15.1 – 100.0)	26/74 (2)
	wlaN	31.8	51.7 (17.4 – 100.0)	164/317 (4)	_	_	-
	htrB	99.8	99.0 (99.0 – 99.0)	101/102 (1)	2.4	28.6 (28.6 – 28.6)	6/21 (1)
	waaC	100.0	99.0 (99.0 – 99.0)	101/102 (1)	96.4	100.0 (100.0 - 100.0)	21/21 (1)
Immune modulation	cstIII	34.8	49.7 (31.4 – 83.6)	78/157 (2)	_	_	_
(lipooligosaccharide; LOS)	neuA	35.1	_	-	_	-	-
	neuB	35.1	33.3 (33.3 – 33.3)	34/102 (1)	1.2	-	_
	neuC	34.6	30.4 (30.4 – 30.4)	31/102 (1)	1.2	4.8 (4.8 – 4.8)	1/21 (1)

\* prevalence of international isolates sourced from international studies [8, 38-40, 51-55]. The point estimate is calculated across all isolates. The range is reported highest and lowest prevalence in the included studies. '-' gene was not screened or reported. † *flaA* gene prevalence in Australia determined from presence of amino acids due to *flaA/flaB* paralog interference at nucleotide sequence level. ‡ *porA* gene prevalence in Australia determined from presence of amino acids due to low read quality.

# 309 Discussion

310 Campylobacteriosis cases in Australia displayed relatively similar disease profiles, although 311 some cases experienced more severe symptoms and outcomes, and *Campylobacter* isolates showed 312 considerable variation in their genome, as in many geographic regions [8]. We found in silico AMR 313 determinants in one-fifth of human clinical isolates, with very few isolates possessing MDR genotypes. 314 Many putative virulence genes were highly conserved across patient case and retail meat isolates, 315 suggesting these may be central to the pathogen's fitness regardless of the ability to cause disease. 316 Others, including those associated with immune modulation in microbiological studies, were far less conserved or even rare in human and food isolates, reflecting their less essential role in Campylobacter 317 318 viability [56]. We did not identify any associations between individual or combinations of virulence 319 genes and severe disease characteristics. However, we did detect an association between certain 320 genes and C. jejuni case isolates compared with food isolates, namely flik, Cj1136, and Cj1138.

321 The spectrum of health outcomes from Campylobacter infections is complex, but host factors 322 including age, comorbidities, and medication use likely play an important determining role [57]. While 323 cases aged between 15 and 34 years were more likely to report a higher modified VSS score, older 324 cases had higher odds of being hospitalised. A previous study systematically describing acute 325 gastroenteritis symptoms by age group similarly found that older adults were more likely to be 326 hospitalised and have severe illness, but reported symptoms decreased with age [58]. A hospital-327 based data linkage study in Australia reported that comorbidities were present in 34.5% of cases, and 328 that hospitalisation rates noticeably increased among patients aged over 60 years [57]. These studies 329 also found increases in invasive infection, hospitalisation, length of illness and mortality accompanied 330 increasing age [57, 58]. Other factors beyond traditional symptoms of gastroenteritis may be more 331 likely to result in hospitalisation for older cases, such as dehydration or loss of appetite [13, 58]. Our 332 study found that over 30% of cases aged ≥35-years-old had used PPIs prior to illness and that use was 333 associated with longer duration of diarrhoea. This is consistent with a data linkage study that found

that PPI use was significantly associated with infectious gastroenteritis hospitalisation [50]. While PPIs are considered a safe and effective medication, approved for long-term use, many patients are unaware of the increased risks of infectious gastrointestinal illness and subsequent hospitalisation that may accompany their use. While certain symptoms may indicate a need for hospitalisation, the overall severity of disease does not necessarily predict hospitalisation. Instead, the age of a case is the most significant determinant of the symptoms they experience and their need for seeking healthcare.

340 While previous genomic epidemiological studies have explored the role of virulence factors in 341 campylobacteriosis, we did not detect any direct relationship between human clinical disease 342 outcomes and the presence of individual virulence genes, combinations of virulence genes, or total 343 number of virulence genes [16, 59]. However, random forest analysis of *C. jejuni* isolates found genes 344 associated with the flagellar hook length gene (flik) and LOS synthesis (Cj1136 and Cj1138) to be more 345 prevalent in case than food isolates. As food is the primary vehicle for *Campylobacter* this finding 346 suggests these genes are important for exposure to translate into clinical disease [60, 61]. 347 *Campylobacter* have developed a symbiotic relationship with avian and mammalian species [62]. 348 There are likely to be a range of genes and gene combinations that have developed to maintain this 349 relationship. Additionally, poultry hosts carry a wide variety of *Campylobacter* as part of their normal 350 flora; genes curated for symbiosis in poultry may cause disease in humans.

351 Animal models have been used to study Campylobacter virulence, but current models are 352 unable to successfully reproduce diarrhoeal illness seen in humans [63-65]. Due to this lack of a suitable animal model, understanding Campylobacter virulence mechanisms remains limited. 353 354 Nevertheless, expression of factors associated with pathogen motility, adhesion, invasion, and toxin 355 production may play a role in *Campylobacter* infection [17, 54, 66, 67]. In this study, the *flhA* and *flaA* 356 genes associated with motility were highly conserved across both C. jejuni and C. coli isolates, consistent with previous findings [19, 38, 54]. Genes associated with adhesion and colonisation of 357 358 epithelial cells (i.e., cadF, jlpA, porA, and pebA) were also highly conserved in our study isolates and in

those investigated previously [38, 52, 54, 55]. In particular, the *cadF* gene is considered an essential gene for adhesion to intestinal cells during the initial stages of campylobacteriosis [17, 52, 54]. Similarly, the presence of the *ciaB* and *flaC* genes are considered critical for the invasion of epithelial cells [66]. However, our study results indicate that even in the absence of *ciaB*, clinical disease can occur.

364 Cytolethal distending toxin (CDT) is a commonly distributed toxin across Gram-negative 365 bacteria (e.g., Shigella and Escherichia coli) and is well characterised in Campylobacter spp. [18, 59]. 366 CDT operates by promoting intestinal epithelial cell damage and death and is implicated in severe 367 illness caused by C. jejuni [19, 68, 69]. Previous studies have suggested that all three gene subunits of 368 the *cdtABC* operon are required for full toxin function [70-72]. Global prevalence of the *cdtABC* operon 369 is high in C. jejuni strains but is variable in C. coli strains; the cdtABC genes were absent in the C. coli 370 isolates in our study and ranged from ~13% to 100% across international studies. A previous study 371 found gene differences between Campylobacter species, attributing this to a reliance on C. jejuni-372 focused research for understanding virulence [40]. We detected high prevalence of the cdtABC operon 373 in *C. jejuni* isolates in our study (>99%), but a previous study comparing diarrhoeal and non-diarrhoeal 374 campylobacteriosis cases detected a much lower prevalence of 76.5% in the non-diarrhoeal cases, 375 indicating that this gene cluster may play a role in development of diarrhoea [8].

The functions of individual genes associated with the LOS (i.e., *htrB, waaC, cstIII, wlaN, neuABC*) are not well defined, but are thought to be implicated in the development of Guillain-Barré syndrome (GBS), an immunoreactive condition where nervous system receptors are targeted and damaged by the host immune response [39]. The function of these genes is to sialyate *Campylobacter* LOS on the surface of *C. jejuni* cells, mimicking sialyation on gangliosides found on human peripheral nerve cells; this molecular mimicry can trigger GBS [73, 74]. The *wlaN, cstIII* and *neuABC* genes were present in approximately one third of *C. jejuni* isolates and were mostly absent in *C. coli*. Further

investigation is needed to elucidate the relationship between the expression of these genes anddevelopment of GBS.

385 In our previously published Australian study of Campylobacter genomics, we reported that 386 the prevalence of AMR determinants was low in Campylobacter isolates compared to other high-387 income countries [30]. Here, we observed a high rate of antibiotic use following infection, regardless 388 of hospitalisation status, length of illness, or case age. Australian prescription guidelines recommend 389 the use of azithromycin, CIP, or norfloxacin for those with severe disease or in vulnerable groups [75]. 390 While AMR is low in Australia, attributed to regulations on the prescription of quinolones in humans 391 and food-producing animals [76], growing levels of AMR is a global issue and antimicrobial 392 stewardship is a priority for public health. High prescription rates should be investigated further to 393 ensure optimal patient care while combating antibiotic resistance. Previous studies have examined 394 relationships between virulence markers and AMR [38, 66, 72], with one study reporting a relationship 395 between resistance to fluoroquinolones and TET and the presence of the virB11 and wlaN genes [38] 396 and another with resistance to TET or ERY and *cdtA* and *dnaJ* genes [72]. We observed some clustering 397 of AMR genes by sequence type but did not identify any relationships between AMR and virulence 398 genes or severe disease outcomes.

399 Our study cases were recruited from among cases notified to a health department, meaning 400 that all cases experienced symptomatic illness requiring care and therefore mild or asymptomatic 401 cases were unlikely to have been recruited [10, 25]. Further, cases from the ACT and NSW were largely 402 recruited from hospital-based laboratory service samples suggesting that our hospitalisation rate is 403 not representative of the general hospitalisation rate for campylobacteriosis. An ACT-based study 404 estimated that 13.6% of campylobacteriosis cases were hospitalised, increasing to 20.0% when non-405 admitted emergency department visits were included [57]. We relied on self-reported symptoms from 406 cases, which may be less reliable than a clinical assessment by a healthcare professional. Some 407 symptoms can be subjective and may not be accurately reported (e.g., fever) or respondents may be

408 reluctant to report them. Older respondents and those with poorer memory or pre-existing health 409 conditions may have experienced issues with recall, particularly when asked about specific symptoms, 410 resulting in recall bias. Finally, we explored a subset of known putative virulence-associated genes 411 sourced from the VFDB. This was not a comprehensive list and did not explore all virulence genes 412 noted in the literature. We included a small number of studies and isolates in our international gene 413 comparison, which is unlikely to be representative of global gene prevalence. As research into 414 virulence determinants continues, further genes and gene combinations should be explored to 415 understand their role in disease.

416 In this study, we did not find direct associations between genetic markers of virulence and 417 disease outcomes for Campylobacter. However, we did detect associations between certain virulence 418 genes and human C. jejuni isolates compared with food isolates. Our study provides valuable insights 419 into the genomic diversity, the prevalence of virulence markers, and the low prevalence of antibiotic 420 resistance among *Campylobacter* isolates. To continue uncovering unknown aspects of the pathogen, 421 Campylobacter surveillance should continue to incorporate WGS to provide high-resolution data, 422 particularly for developing baseline estimates of genomic characteristics in mild, moderate, and severe disease to understand associations with severity. To support this, researchers conducting 423 424 cohort studies should consider examining virulence factor prevalence between symptomatic and 425 asymptomatic cases, as well as the development of more severe sequelae such as GBS in cases. Future 426 studies in Australia should follow international studies that have investigated the presence or absence 427 of certain virulence genes, AMR, and the molecular relationships between human clinical and source 428 isolates to enable a more comprehensive understanding of the pathogenesis of campylobacteriosis 429 [38, 77, 78].

430

# 432 Acknowledgements

433 The authors would like to thank the extended CampySource Project team, reference panel, and 434 additional contributors to the study. The CampySource Project team comprises three working groups 435 and a reference panel. The working groups focus on food and animal sampling, epidemiology and 436 modelling, and genomics. The reference panel includes expert representatives from government and 437 industry. The study includes the following partner organisations: the Australian National University, 438 Massey University, University of Melbourne, Queensland Health, Queensland Health Forensic and 439 Scientific Services, New South Wales Food Authority, New South Wales Health, Hunter New England 440 Health, Victorian Department of Health and Human Services, Food Standards Australia New Zealand, 441 Commonwealth Department of Health and AgriFutures Australia–Chicken Meat Program. 442 CampySource also collaborates with the following organisations: ACT Health, Sullivan Nicolaides 443 Pathology, University of Queensland, Primary Industries and Regions South Australia, Department of 444 Health and Human Services Tasmania, Meat and Livestock Australia, and New Zealand Ministry for 445 Primary Industries.

446 The CampySource Project Team consists of: Nigel P French, Massey University, New Zealand; Mary 447 Valcanis, The University of Melbourne; Dieter Bulach, The University of Melbourne; Emily Fearnley, 448 South Australian Department for Health and Wellbeing; Russell Stafford, Queensland Health; Amy Jennison, Queensland Health; Trudy Graham, Queensland Health; Keira Glasgow, Health Protection 449 450 NSW; Kirsty Hope, Health Protection NSW; Themy Saputra, NSW Food Authority; Craig Shadbolt, NSW 451 Food Authority; Arie Havelaar, The University of Florida, USA; Joy Gregory, Department of Health and 452 Human Services, Victoria; James Flint, Hunter New England Health; Simon Firestone, The University of 453 Melbourne; James Conlan, Food Standards Australia New Zealand; Ben Daughtry, Food Standards 454 Australia New Zealand; James J Smith, Queensland Health; Heather Haines, Department of Health and 455 Human Services, Victoria; Sally Symes, Department of Health and Human Services, Victoria; Barbara 456 Butow, Food Standards Australia New Zealand; Liana Varrone, The University of Queensland; Linda 457 Selvey, The University of Queensland; Tim Sloan-Gardner, ACT Health; Deborah Denehy, ACT Health;

458 Radomir Krsteski, ACT Health; Natasha Waters, ACT Health; Kim Lilly, Hunter New England Health; 459 Julie Collins, Hunter New England Health; Tony Merritt, Hunter New England Health; Rod Givney, 460 Hunter New England Health; Joanne Barfield, Hunter New England Health; Ben Howden, The 461 University of Melbourne; Kylie Hewson, AgriFutures Australia–Chicken Meat Program; Dani Cribb, The 462 Australian National University; Rhiannon Wallace, The Australian National University; Angus McLure, The Australian National University; Ben Polkinghorne, The Australian National University; Cameron 463 464 Moffatt, The Australian National University; Martyn Kirk, The Australian National University; and 465 Kathryn Glass, The Australian National University.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297105; this version posted October 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY 4.0 International license .

#### References 466

- 467 1. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global Epidemiology of 468 Campylobacter Infection. Clin Microbiol Rev. 2015;28(3):687-720. doi: 10.1128/CMR.00006-469 15. PubMed PMID: 26062576.
- 470 2. Australian Government Department of Health and Aged Care. National Notifiable Disease 471 Surveillance System - National Communicable Disease Surveillance Dashboard 2023. 472 Available from: https://nindss.health.gov.au/pbi-dashboard/.
- 473 3. European Food Safety Authority, European Centre for Disease Prevention and Control. The 474 European Union One Health 2019 Zoonoses Report. EFSA J. 2021;19(2):e06406. doi: 475 10.2903/j.efsa.2021.6406.
- 476 Centers for Disease Control and Prevention. FoodNet Fast - Pathogen Surveillance 2022 4. 477 [cited 2023 February]. Available from: cdc.gov/foodnetfast/.
- 478 5. Varrone L, Glass K, Stafford RJ, Kirk MD, Selvey L, CampySource Project Team. A meta-479 analysis of case-control studies examining sporadic campylobacteriosis in Australia and New 480 Zealand from 1990 to 2016. Aust N Z J Public Health. 2020;44(4):313-9. doi: 481 https://doi.org/10.1111/1753-6405.12998.
- 482 6. Cribb DM, Varrone L, Wallace RL, McLure AT, Smith JJ, Stafford RJ, et al. Risk factors for 483 campylobacteriosis in Australia: outcomes of a 2018–2019 case–control study. BMC Infect 484 Dis. 2022;22(1):586. doi: 10.1186/s12879-022-07553-6.
- 485 7. Acheson D, Allos BM. Campylobacter jejuni Infections: Update on Emerging Issues and 486 Trends. Clinical Infectious Diseases. 2001;32(8):1201-6. doi: 10.1086/319760.
- 487 8. Wysok B, Wojtacka J, Hänninen M-L, Kivistö R. Antimicrobial Resistance and Virulence-488 Associated Markers in Campylobacter Strains From Diarrheic and Non-diarrheic Humans in Poland. Frontiers in Microbiology. 2020;11. doi: 10.3389/fmicb.2020.01799. 489
- 490 9. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed 491 Res Int. 2013;2013:340605. Epub 2013/07/19. doi: 10.1155/2013/340605. PubMed PMID: 492 23865047; PubMed Central PMCID: PMCPMC3707206.
- 493 10. Elnegaard S, Andersen RS, Pedersen AF, Larsen PV, Søndergaard J, Rasmussen S, et al. Self-494 reported symptoms and healthcare seeking in the general population--exploring "The 495 Symptom Iceberg". BMC Public Health. 2015;15:685. Epub 2015/07/22. doi:
- 496 10.1186/s12889-015-2034-5. PubMed PMID: 26195232; PubMed Central PMCID: 497 PMCPMC4509464.
- 498 11. McAteer A, Elliott AM, Hannaford PC. Ascertaining the size of the symptom iceberg in a UK-499 wide community-based survey. Br J Gen Pract. 2011;61(582):e1-11. Epub 2011/03/16. doi: 10.3399/bjgp11X548910. PubMed PMID: 21401979; PubMed Central PMCID: 500 501 PMCPMC3020067.
- 502 12. Gillespie IA, apos, Brien SJ, Frost JA, Tam C, Tompkins D, et al. Investigating vomiting and/or 503 bloody diarrhoea in Campylobacter jejuni infection. Journal of Medical Microbiology. 504 2006;55(6):741-6. doi: https://doi.org/10.1099/jmm.0.46422-0.
- 505 Hall G, Kirk M, Ashbolt R, Gregory J, Lalor K, Millard G, et al. Results from the National 13. 506 Gastroenteritis Survey 2001 - 2002. National Centre for Epidemiology and Population Health, 507 The Australian National University, 2004.
- 508 Wallace RL, Cribb DM, Bulach DM, Ingle DJ, Joensen KG, Nielsen EM, et al. Campylobacter 14. 509 jejuni ST50, a pathogen of global importance: A comparative genomic analysis of isolates 510 from Australia, Europe and North America. Zoonoses and Public Health. 2021;68(6):638-49. 511 doi: https://doi.org/10.1111/zph.12853.
- 512 15. Djeghout B, Bloomfield SJ, Rudder S, Elumogo N, Mather AE, Wain J, et al. Comparative 513 genomics of Campylobacter jejuni from clinical campylobacteriosis stool specimens. Gut 514 Pathogens. 2022;14(1):45. doi: 10.1186/s13099-022-00520-1.
- 515 16. Dasti JI, Tareen AM, Lugert R, Zautner AE, Groß U. Campylobacter jejuni: A brief overview on 516 pathogenicity-associated factors and disease-mediating mechanisms. International Journal

polpotal	·y·
It is made available under a CC-E	3Y 4.0 International license .

517		of Medical Microbiology. 2010;300(4):205-11. doi:
518		https://doi.org/10.1016/j.ijmm.2009.07.002.
519	17.	de Oliveira MG, Rizzi C, Galli V, Lopes GV, Haubert L, Dellagostin OA, et al. Presence of genes
520		associated with adhesion, invasion, and toxin production in Campylobacter jejuni isolates
521		and effect of temperature on their expression. Can J Microbiol. 2019;65(4):253-60. Epub
522		2018/12/12. doi: 10.1139/cjm-2018-0539. PubMed PMID: 30532987.
523	18.	Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. Campylobacter spp. as a
524		Foodborne Pathogen: A Review. Front Microbiol. 2011;2:200. Epub 2011/10/13. doi:
525		10.3389/fmicb.2011.00200. PubMed PMID: 21991264; PubMed Central PMCID:
526		PMCPMC3180643.
527	19.	Ramires T, de Oliveira MG, Kleinubing NR, de Fátima Rauber Würfel S, Mata MM, Iglesias
528		MA, et al. Genetic diversity, antimicrobial resistance, and virulence genes of thermophilic
529		Campylobacter isolated from broiler production chain. Braz J Microbiol. 2020;51(4):2021-32.
530		Epub 2020/06/10. doi: 10.1007/s42770-020-00314-0. PubMed PMID: 32514993: PubMed
531		Central PMCID: PMCPMC7688733.
532	20.	Bolton DJ. Campylobacter virulence and survival factors. Food Microbiol. 2015:48:99-108.
533		Epub 2015/03/21, doi: 10.1016/i fm 2014.11.017, PubMed PMID: 25790997
534	21	Varrone I Stafford RI Lilly K Selvey I Glass K Ford L et al Investigating locally relevant risk
525	21.	factors for <i>Campulobacter</i> infection in Australia: protocol for a case-control study and
536		genomic analysis BMI Open 2018;8(12);e026630 doi: 10.1136/hmiopen-2018-026630
537	22	Ruuska T. Vesikari T. Rotavirus Disease in Finnish Children: Use of Numerical Scores for
538	22.	Clinical Severity of Diarrhogal Enjodes, Scandinavian Journal of Infectious Diseases
530		1990.22/3).259-67 doi: 10.3109/003655/90090270/6
535	22	Schnadower D. Tarr PL. Goralick MH. O'Connell K. Roskind CG. Rowell EC. et al. Validation of
540	25.	the modified Vesikari score in children with gastroenteritis in 5 US emergency departments
541		Le mounned vesikari score in children with gast bententis in 5 05 emergency departments.
542 E12		10 1007/MPC 0b012c21920cc5c2, DubMed DMD: 22676445, DubMed Control DMCID:
545 E 1 1		
544 545	24	PIVICPIVIC3/88842.
545	24.	Shim DH, Kim DY, Cho KY. Diagnostic value of the vesikari Scoring System for predicting the
540		Viral of bacterial pathogens in pediatric gastroenteritis. Korean J Pediatr. 2016;59(3):126-31.
547		Epub 2016/05/18. doi: 10.3345/Kjp.2016.59.3.126. PubMed PMID: 27186219; PubMed
548	25	Central PMCD: PMCPMC4865623.
549	25.	Hall G, Yonannes K, Raupach J, Becker N, Kirk M. Estimating community incidence of
550		Salmonella, Campylobacter, and Shiga toxin-producing Escherichia coli infections, Australia.
551		Emerg Infect Dis. 2008;14(10):1601-9. Epub 2008/10/02. doi: 10.3201/eid1410.0/1042.
552		PubMed PMID: 18826825; PubMed Central PMCID: PMCPMC2609882.
553	26.	Walker LJ, Wallace RL, Smith JJ, Graham T, Saputra T, Symes S, et al. Prevalence of
554		Campylobacter coli and jejuni in retail chicken, beef, lamb and pork products in three
555		Australian states. Journal of Food Protection. 2019;82(12):2126-34.
556	27.	Wallace RL, Bulach DM, Jennison AV, Valcanis M, McLure A, Smith JJ, et al. Molecular
557		characterization of Campylobacter spp. recovered from beef, chicken, lamb and pork
558		products at retail in Australia. PLOS ONE. 2020;15(7):e0236889. doi:
559		10.1371/journal.pone.0236889.
560	28.	Jolley KA, Bray, J. E., & Maiden, M. C. J. Open-access bacterial population genomics: BIGSdb
561		software, the PubMLST.org website and their applications. Wellcome Open Res.
562		2018;3(124). doi: 10.12688/ wellc omeop enres.14826.1.
563	29.	Liu B, Zheng D, Zhou S, Chen L, Yang J. VFDB 2022: a general classification scheme for
564		bacterial virulence factors. Nucleic Acids Res. 2022;50(D1):D912-d7. doi:
565		10.1093/nar/gkab1107. PubMed PMID: 34850947; PubMed Central PMCID:
566		PMCPMC8728188.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297105; this version posted October 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

567 30. Wallace R, Bulach D, McLure A, Varrone L, Jennison A, Valcanis M, et al. Antimicrobial 568 Resistance of Campylobacter spp. Causing Human Infection in Australia: An International 569 Comparison. Microb Drug Resist. 2021;27(4):518-28. doi: 10.1089/mdr.2020.0082. PubMed 570 PMID: 32898460. Zeng X, Brown S, Gillespie B, Lin J. A single nucleotide in the promoter region modulates the 571 31. 572 expression of the  $\beta$ -lactamase OXA-61 in Campylobacter jejuni. J Antimicrob Chemother. 573 2014;69(5):1215-23. Epub 2014/01/11. doi: 10.1093/jac/dkt515. PubMed PMID: 24408987. 574 32. Ladely SR, Meinersmann RJ, Englen MD, Fedorka-Cray PJ, Harrison MA. 23S rRNA gene 575 mutations contributing to macrolide resistance in Campylobacter jejuni and Campylobacter 576 coli. Foodborne Pathog Dis. 2009;6(1):91-8. Epub 2008/11/19. doi: 10.1089/fpd.2008.0098. 577 PubMed PMID: 19014274. 578 33. Hakanen A, Jalava J, Kotilainen P, Jousimies-Somer H, Siitonen A, Huovinen P. gyrA 579 polymorphism in Campylobacter jejuni: detection of gyrA mutations in 162 C. jejuni isolates 580 by single-strand conformation polymorphism and DNA sequencing. Antimicrob Agents 581 Chemother. 2002;46(8):2644-7. Epub 2002/07/18. doi: 10.1128/aac.46.8.2644-2647.2002. 582 PubMed PMID: 12121947; PubMed Central PMCID: PMCPMC127378. 583 34. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 584 2010;13(6):151-71. Epub 2010/09/14. doi: 10.1016/j.drup.2010.08.003. PubMed PMID: 20833577; PubMed Central PMCID: PMCPMC2992599. 585 586 35. Whitehouse CA, Young S, Li C, Hsu CH, Martin G, Zhao S. Use of whole-genome sequencing 587 for Campylobacter surveillance from NARMS retail poultry in the United States in 2015. Food 588 Microbiol. 2018;73:122-8. Epub 2018/03/13. doi: 10.1016/j.fm.2018.01.018. PubMed PMID: 589 29526197. 590 Qin S, Wang Y, Zhang Q, Zhang M, Deng F, Shen Z, et al. Report of ribosomal RNA methylase 36. 591 gene erm(B) in multidrug-resistant Campylobacter coli. J Antimicrob Chemother. 592 2014;69(4):964-8. Epub 2013/12/18. doi: 10.1093/jac/dkt492. PubMed PMID: 24335515. 593 37. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-594 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert 595 proposal for interim standard definitions for acquired resistance. Clinical Microbiology and 596 Infection. 2012;18(3):268-81. doi: https://doi.org/10.1111/j.1469-0691.2011.03570.x. 597 Wieczorek K, Wołkowicz T, Osek J. Antimicrobial Resistance and Virulence-Associated Traits 38. 598 of Campylobacter jejuni Isolated From Poultry Food Chain and Humans With Diarrhea. Frontiers in Microbiology. 2018;9. doi: 10.3389/fmicb.2018.01508. 599 600 39. Quino W, Caro-Castro J, Hurtado V, Flores-León D, Gonzalez-Escalona N, Gavilan RG. 601 Genomic Analysis and Antimicrobial Resistance of Campylobacter jejuni and Campylobacter 602 coli in Peru. Frontiers in Microbiology. 2022;12. doi: 10.3389/fmicb.2021.802404. 603 40. Bravo V, Katz A, Porte L, Weitzel T, Varela C, Gonzalez-Escalona N, et al. Genomic analysis of 604 the diversity, antimicrobial resistance and virulence potential of clinical Campylobacter jejuni 605 and Campylobacter coli strains from Chile. PLoS Negl Trop Dis. 2021;15(2):e0009207. Epub 2021/02/20. doi: 10.1371/journal.pntd.0009207. PubMed PMID: 33606689; PubMed Central 606 607 PMCID: PMCPMC7928456. 608 41. Breinman L, Cutler A, Liaw A, Wiener M. randomForest: Breiman and Cutler's Random 609 Forests for Classification and Regression 2022. Available from: https://cran.r-610 project.org/web/packages/randomForest/index.html. 611 42. Kuhn M, Wing J, Weston S, Williams A, Keefer C, Engelhardt A, et al. caret: Classification and 612 Regression Training 2023. Available from: https://cran.r-project.org/web/packages/caret/. 613 43. Kooperberg C, Ruczinski I. LogicReg: Logic Regression. 2022. 614 44. Gibb S, Strimmer K. binda: Multi-Class Discriminant Analysis using Binary Predictors 2021. 615 Available from: https://cran.r-project.org/web/packages/binda/index.html. 616 45. R Core Team. R: A language and environment for statistical computing. R Foundation for 617 Statistical Computing. Vienna, Austria Available from: https://www.R-project.org/.

618 46. Wood S. mgcv: Mixed GAM Computation Vehicle with Automatic Smoothness Estimation 619 2023. Available from: https://cran.r-project.org/web/packages/mgcv/index.html. 620 47. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Research. 2021;49(W1):W293-W6. doi: 621 622 10.1093/nar/gkab301. 623 48. Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics 2023. Available from: 624 625 https://cran.r-project.org/web/packages/ggplot2/index.html. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton 626 49. 627 pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749-56. Epub 628 2015/12/30. doi: 10.1136/gutjnl-2015-310861. PubMed PMID: 26719299. 629 50. Chen Y, Liu B, Glass K, Du W, Banks E, Kirk M. Use of Proton Pump Inhibitors and the Risk of 630 Hospitalization for Infectious Gastroenteritis. PloS one. 2016;11(12):e0168618-e. doi: 631 10.1371/journal.pone.0168618. PubMed PMID: 27997598. 632 51. González-Hein G, Huaracán B, García P, Figueroa G. Prevalence of virulence genes in strains 633 of Campylobacter jejuni isolated from human, bovine and broiler. Braz J Microbiol. 2013;44(4):1223-9. Epub 2014/04/02. doi: 10.1590/s1517-83822013000400028. PubMed 634 635 PMID: 24688515; PubMed Central PMCID: PMCPMC3958191. 636 52. Biswas D, Hannon SJ, Townsend HG, Potter A, Allan BJ. Genes coding for virulence 637 determinants of Campylobacter jejuni in human clinical and cattle isolates from Alberta, 638 Canada, and their potential role in colonization of poultry. Int Microbiol. 2011;14(1):25-32. 639 Epub 2011/10/22. doi: 10.2436/20.1501.01.132. PubMed PMID: 22015699. 640 53. Lluque A, Riveros M, Prada A, Ochoa TJ, Ruiz J. Virulence and Antimicrobial Resistance in 641 Campylobacter spp. from a Peruvian Pediatric Cohort. Scientifica (Cairo). 642 2017;2017:7848926. Epub 2017/11/14. doi: 10.1155/2017/7848926. PubMed PMID: 643 29130018; PubMed Central PMCID: PMCPMC5654289. 54. 644 Casabonne C, Gonzalez A, Aquili V, Subils T, Balague C. Prevalence of Seven Virulence Genes 645 of Campylobacter jejuni Isolated from Patients with Diarrhea in Rosario, Argentina. 646 2016;3(4):e37727. Epub 2016-08-01. doi: 10.17795/iji-37727. 647 55. Kim JS, Lee MY, Kim SJ, Jeon S-E, Cha I, Hong S, et al. High-Level Ciprofloxacin-Resistant Campylobacter jejuni Isolates Circulating in Humans and Animals in Incheon, Republic of 648 649 Korea. Zoonoses and Public Health. 2016;63(7):545-54. doi: https://doi.org/10.1111/zph.12262. 650 651 56. Marsden GL, Li J, Everest PH, Lawson AJ, Ketley JM. Creation of a Large Deletion Mutant of 652 <i>Campylobacter jejuni</i> Reveals that the Lipooligosaccharide Gene Cluster Is Not 653 Required for Viability. Journal of Bacteriology. 2009;191(7):2392-9. doi: 654 doi:10.1128/jb.01397-08. 57. Moffatt CRM, Kennedy KJ, Selvey L, Kirk MD. Campylobacter-associated hospitalisations in 655 656 an Australian provincial setting. BMC Infectious Diseases. 2021;21(1):10. doi: 657 10.1186/s12879-020-05694-0. 658 58. White AE, Ciampa N, Chen Y, Kirk M, Nesbitt A, Bruce BB, et al. Characteristics of 659 Campylobacter and Salmonella Infections and Acute Gastroenteritis in Older Adults in 660 Australia, Canada, and the United States. Clin Infect Dis. 2019;69(9):1545-52. Epub 2019/01/03. doi: 10.1093/cid/ciy1142. PubMed PMID: 30602004; PubMed Central PMCID: 661 PMCPMC6606397. 662 59. 663 Quetz JdS, Lima IFN, Havt A, Prata MMG, Cavalcante PA, Medeiros PHQS, et al. 664 Campylobacter jejuni infection and virulence-associated genes in children with moderate to 665 severe diarrhoea admitted to emergency rooms in northeastern Brazil. Journal of Medical Microbiology. 2012;61(4):507-13. doi: https://doi.org/10.1099/jmm.0.040600-0. 666 667 60. Kamal N, Dorrell N, Jagannathan A, Turner SM, Constantinidou C, Studholme DJ, et al. 668 Deletion of a previously uncharacterized flagellar-hook-length control gene flik modulates

669		the σ54-dependent regulon in Campylobacter jejuni, Microbiology, 2007;153(9);3099-111.
670		doi: https://doi.org/10.1099/mic.0.2007/007401-0.
671	61.	Javed MA. Cawthraw SA. Baig A. Li J. McNally A. Oldfield NJ. et al. Ci1136 is required for
672	•	lipooligosaccharide biosynthesis, hyperinvasion, and chick colonization by Campylobacter
673		ieiuni, Infect Immun, 2012:80(7):2361-70. Epub 20120416. doi: 10.1128/iai.00151-12.
674		PubMed PMID: 22508861: PubMed Central PMCID: PMCPMC3416457
675	62	Rukambile F. Sintchenko V. Muscatello G. Kock R. Alders R. Infection, colonization and
676	02.	shedding of Campylobacter and Salmonella in animals and their contribution to human
677		disease: A review Zoonoses and nublic health 2019:66(6):562-78
678	63	Lones GV Ramires T Kleinuhing NR Scheik LK Eigrentini ÂM Padilha da Silva W Virulence
679	03.	factors of foodborne nathogen Campylobacter jejuni. Microhial Pathogenesis
680		2021:161:105265, doi: https://doi.org/10.1016/i.micrath.2021.105265
681	64	Bacon DI Szymanski CM Burr DH Silver RP Alm RA Guerry P A phase-variable cancule is
607	04.	involved in virulence of Compulabactor jointi 81, 176. Molecular Microbiology
682		2001(40/2), $760.77$ , doi: https://doi.org/10.1046/i.1265.2058.2001.02421.v
601	65	Z001,40(5).705-77. doi: https://doi.org/10.1040/j.1505-2558.2001.02451.X.
004 605	05.	isiuni mediated enteritic. Current iscues in intestinal microbiology, 2001;2(2):EE, 71
605	66	Chungim H. Bohnko IM. Aigha I. Sharma A. Doinhada SH. Dochmukh A. et al. Analysis of
000	00.	Giunaliii H, Bellike JW, Algila I, Sharina A, Dolphoue SH, Deshinukii A, et al. Analysis of
007		Compulshaster isolates from Datients with Sovere Diarrhoad, DIOS ONE
000		Campyiobacter isolates from Patients with Severe Diarmoed. PLOS ONE.
089	67	2015;10(3):e0119208. 001: 10.1371/j00111di.p01e.0119208.
090 C01	67.	Kreinig V, Falcone FH, Kenrenberg C, Hensel A. Campylobacter sp.: Pathogenicity factors and
691		prevention methods—new molecular targets for innovative antivirulence drugs? Applied
692		Microbiology and Biotechnology. 2020;104(24):10409-36. doi: 10.1007/S00253-020-10974-
693	60	5. Militahawaa CA, Ballia DD, Daasi EC, Cattle DL, Minahita DM, Diahatt CL, Cananylahaattan jajumi
694 COF	68.	whitehouse CA, Baido PB, Pesci EC, Cottie DL, Mirabito PM, Pickett CL. Campyiobacter jejuni
695		cycoletnal distending toxin causes a G2-phase cell cycle block. Infect immun.
696		1998;66(5):1934-40. Epub 1998/05/09. doi: 10.1128/181.66.5.1934-1940.1998. Publyled
697	60	
698	69.	HICKEY IE, MICVEIGN AL, SCOTT DA, MICHIEIUTTI RE, BIXDY A, Carroll SA, et al. Campylobacter
699		jejuni cytoletnal distending toxin mediates release of interleukin-8 from intestinal epithelia
700		cells. Infect Immun. 2000;68(12):6535-41. Epub 2000/11/18. doi: 10.1128/iai.68.12.6535-
701	70	6541.2000. Publied PMID: 11083762; Publied Central PMCID: PMCPMC97747.
702	70.	Asakura M, Samosornsuk W, Hinenoya A, Misawa N, Nishimura K, Matsunisa A, et al.
703		Development of a cytolethal distending toxin (cdt) gene-based species-specific multiplex PCR
704		assay for the detection and identification of Campylobacter jejuni, Campylobacter coll and
705		Campylobacter fetus. FEMS Immunol Med Microbiol. 2008;52(2):260-6. Epub 2008/02/06.
706		doi: 10.1111/j.15/4-695X.2007.00369.x. PubMed PMID: 18248435.
/0/	/1.	Park SF. The physiology of Campylobacter species and its relevance to their role as
/08		foodborne pathogens. International Journal of Food Microbiology. 2002;74(3):177-88. doi:
709		https://doi.org/10.1016/S0168-1605(01)00678-X.
710	72.	Lapierre L, Gatica MA, Riquelme V, Vergara C, Yañez JM, San Martin B, et al. Characterization
711		of antimicrobial susceptibility and its association with virulence genes related to adherence,
712		invasion, and cytotoxicity in Campylobacter jejuni and Campylobacter coli isolates from
713		animals, meat, and humans. Microbial Drug Resistance. 2016;22(5):432-44.
714	73.	Hansson I, Sandberg M, Habib I, Lowman R, Engvall EO. Knowledge gaps in control of
715		Campylobacter for prevention of campylobacteriosis. Transboundary and Emerging Diseases.
716		2018;65(S1):30-48. doi: https://doi.org/10.1111/tbed.12870.
717	74.	Godschalk PCR, Kuijf ML, Li J, Michael FS, Ang CW, Jacobs BC, et al. Structural

719 Guillain-Barré and Miller Fisher Syndromes. Infection and Immunity. 2007;75(3):1245-54. doi: doi:10.1128/IAI.00872-06. 720 Therapeutic Guidelines Limited. Acute infectious diarrhoea 2022 [cited 2023 26 June]. 721 75. Available from: 722 https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=ac 723 724 ute-gastroenteritis&guidelinename=Antibiotic&sectionId=toc d1e521#toc d1e521. 725 Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone 76. 726 resistance through successful regulation, Australia. Emerg Infect Dis. 2012;18(9):1453-60. doi: 10.3201/eid1809.111515. PubMed PMID: 22932272; PubMed Central PMCID: 727 728 PMCPMC3437704. Andrzejewska M, Grudlewska-Buda K, Śpica D, Skowron K, Ćwiklińska-Jurkowska M, Szady-729 77. Grad M, et al. Genetic relatedness, virulence, and drug susceptibility of Campylobacter 730 731 isolated from water and wild birds. Frontiers in Cellular and Infection Microbiology. 2022;12.

732 doi: 10.3389/fcimb.2022.1005085.

- 73378.Wysok B, Wojtacka J, Kivistö R. Pathogenicity of Campylobacter strains of poultry and human734origin from Poland. International Journal of Food Microbiology. 2020;334:108830. doi:725human (1/14) and (1016) (10
- 735 https://doi.org/10.1016/j.ijfoodmicro.2020.108830.

736

#### **Figure captions** 738

- Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches, 739
- 740 nausea, and stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis
- 741 cases (blood in stool, fever, headache, and vomiting), 2018–2019. (c) Course of disease
- 742 characteristics of Australian campylobacteriosis cases (hospitalisation, hospitalisation  $\geq$ 3 days,
- 743 length of illness ≥7 days), 2018–2019. The solid lines indicate estimated prevalence from a
- 744 univariable generalised additive model with a logit link. Shading around each line represents the 95%
- 745 confidence interval for the prevalence estimate.
- Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in 746
- 747 Australia, 2018–2019. Bars represent the percentage of cases reporting the corresponding Vesikari
- 748 Score. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact
- 749 method. Counts are provided above the bar for each Vesikari Score.
- 750 Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis
- 751 cases in Australia, 2018–2019. The solid line indicates the estimated score from a generalised
- 752 additive model with a logit link. Shading around the line represents the 95% confidence interval for 753 the score estimate.
- Fig 4. Genotypic antimicrobial resistance profiles of 506 Campylobacter isolates for ampicillin 754
- 755 (AMP), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET). Isolates
- 756 were classified as susceptible if they did not possess a known resistance gene or mutation (n = 403).
- 757 The number of isolates possessing each resistance profile is noted above the respective bar. Error bars
- 758 are calculated from binomial confidence intervals using the Pearson-Klopper exact method.

#### Supporting Information 759

- 760 S1 Table: Antimicrobial resistance genes and mutations used to infer phenotypic resistance in
- 761 Campylobacter isolates.
- 762 S2 Table. Summary of Campylobacter isolates (n = 1122) included in this study.
- 763 S3 Table. Univariable results for hospitalisation, adjusted for age group, sex, and location, and
- 764 final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI: confidence interval, ref: 765 reference category, Inf: no limit on confidence interval.
- 766 S4 Table. Univariable results for prescription of antibiotics following illness, adjusted for age
- 767 group, sex, and location, and final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI: 768 confidence interval, ref: reference category, Inf: no limit on confidence interval.
- 769 S5 Table. Univariable results for length of diarrhoeal illness, adjusted for age group, sex, and
- location, and final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI: confidence 770 771 interval, ref: reference category, Inf: no limit on confidence interval.
- 772 S6 Table: Summary of multi-locus sequence type (MLST) and virulence gene prevalence in
- 773 Campylobacter jejuni and C. coli human isolates.
- 774 S7 Table. Comparison of isolate virulence gene prevalence between human and retail meat
- 775 isolates, Australia, 2018–2019. N/A: no gene present, or no analysis possible due to zero levels. \* 776 indicates significant result (p < 0.05).
- S1 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for 777
- 778 C. jejuni human isolates. The colour scale represents the proportion of isolates within each MLST
- 779 expressing each virulence gene.

- 780 S2 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for
- 781 *C. coli* human isolates. The colour scale represents the proportion of isolates within each MLST
   782 expressing each virulence gene.
- 783 S3 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between C.

*jejuni* isolates (*n* = 422) from humans in the Australian Capital Territory (ACT), New South Wales

785 (NSW), and Queensland (Qld). The circle lanes from inner to outer indicate jurisdiction, multilocus

- r86 sequence type (MLST), the number of class of antimicrobial genotype detected, and the number andrait class of virulence genotype detected.
- 788 S4 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between *C*.
- 789 *coli* isolates (*n* = 84) from humans in the Australian Capital Territory (ACT), New South Wales
- (NSW), and Queensland (QLD). The circle lanes from inner to outer indicate jurisdiction, multilocus
   sequence type (MLST), the number and class of antimicrobial genotype detected, and the number
- 792 and trait class of virulence genotype detected.
- 793 S5 Fig. Relative importance by Gini\* coefficient of Campylobacter jejuni virulence genes for 794 predicting case isolates^ compared with meat isolates in Australia, 2018–2019. \* Mean decrease in Gini coefficient measures how much of each variable contributes to the homogeneity of the nodes 795 796 and leaves in the random forest. The higher the value of mean decrease Gini score, the higher the 797 importance of the variable. Values should be considered relative to those of other variables rather 798 than absolute values. ^Genes more common in case isolates include flik, Cj1136, Cj1138, Cj1135, maf4, 799 neuC, rfbC, wlaN, cysC, Cj1422c, Cj1421c, gmhA2, kpsC, waaV, fcl, Cj1420c, ciaB, and Cj1419c although 800 not all differences in gene prevalence are significant (p < 0.05).
- S1 File. Random Forest model outputs for *Campylobacter jejuni* and *C. coli* determining virulence
   genes that predict hospitalisation or length of diarrhoeal illness in Australia, 2018–2019.
- 803 S2 File. Random Forest model outputs determining virulence genes that predict a human case
- 804 compared with retail meat and offal isolates in Australia, 2018–2019.
- 805